Canon Medical Receives FDA Clearance for Aquilion ONE / PRISM Edition, Enabling Deep Learning Spectral Capabilities for Routine Use

Spectral CT with Advanced intelligent Clear-IQ Engine (AiCE) Empowers Physicians with Deep Intelligence to Enable Routine Confident Diagnoses

Canon Medical Systems USA, Inc. has received 510(k) clearance for the Aquilion ONE / PRISM Edition, enabling Deep Learning Spectral capabilities that allow for more routine spectral imaging.

Designed for deep intelligence, the advanced system integrates artificial intelligence (AI) technology to maximize conventional and spectral CT capabilities with automated workflows, while providing deep clinical insights to assist physicians in making more informed decisions across the patient’s care cycle.

An innovative approach to CT reconstruction, Advanced intelligent Clear-IQ Engine (AiCE) on the Aquilion ONE / PRISM Edition uses Deep Learning to distinguish true signal from noise to deliver sharp, clear and distinct images at fast speeds. Trained using vast amounts of high-quality image data, AiCE provides enhanced anatomical resolution across the whole body including brain, lung, cardiac and musculoskeletal applications. By enabling Deep Learning Spectral reconstruction, the Aquilion ONE / PRISM Edition helps physicians make more confident diagnoses with the spectral benefits of rapid kV switching with patient-specific mA modulation, full field of view acquisition and 16 cm of coverage, overcoming traditional trade-offs with spectral imaging. The fully integrated end-to-end workflow is seamless and can be incorporated into routine protocols.

“Canon Medical’s DLR technology is pushing routine diagnostic imaging into the age of AI assisted imaging, revolutionizing patient care by enabling excellent diagnostic confidence,” said Erin Angel, managing director, CT Business Unit, Canon Medical Systems USA, Inc. “With Deep Learning Spectral, Canon Medical is able to provide clinicians with a spectral CT system designed to address the trade-offs of traditional spectral CT and potentially expanding the utilization to more routine CT imaging.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”